TICKERNERD
Menu
IMNMIMNMHealthcare · Biotechnology

IMNM Stock Forecast: Immunome, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$20
−3.89% on the day

The 17 Wall Street analysts covering Immunome, Inc. hold a median 12-month price target of $36 — +84.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.3B
Ticker Nerd rank
33/ 100
Median analyst target
$36
Analysts covering
17
Revenue$0.0−100.0% y/y
Operating income−$78.1M
Net income−$73.1M
Free cash flow−$63.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.1%
1M
−6.6%
YTD
−9.1%
1Y
+26.7%
From 52W high
−34.6%
From 52W low
+28.1%
$15
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMNM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immunome, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
33/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
87
Value
63
Volatility
61
Quality
55
Size
33
Accruals
33
Revisions
32
Growth
29
Issuance
23

Momentum (87): The shares have been drifting up relative to others.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IMNM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMNM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Jan 26Apr 26Jul 26Oct 26IMNMHigh $40Median $36Low $24

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
16 Buy1 Hold0 Sell
Low $24Median $36High $40

The green dot is the last close — the median target sits +84.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Oct 2026WedbushReiteratesOutperform$35
16 Oct 2026William BlairInitiatesOutperform—
16 Oct 2026William BlairInitiatesOutperform—
1 Oct 2026StifelInitiatesHold$24
1 Oct 2026StifelInitiatesHold—
21 Sept 2026Alliance Global PartnersInitiatesBuy—
21 Sept 2026Alliance Global PartnersInitiatesBuy$32
10 Sept 2026HC Wainwright & Co.ReiteratesBuy$40
10 Sept 2026HC Wainwright & Co.ReiteratesBuy—
12 Aug 2026Truist SecuritiesMaintainsBuy—
12 Aug 2026Truist SecuritiesMaintainsBuy$37 → $38
12 Aug 2026WedbushMaintainsOutperform—
12 Aug 2026WedbushMaintainsOutperform$31 → $35
21 July 2026WedbushReiteratesOutperform—
21 July 2026WedbushReiteratesOutperform$31
12 June 2026WedbushReiteratesOutperform—
12 June 2026WedbushReiteratesOutperform$31
28 May 2026BarclaysInitiatesOverweight—
28 May 2026Truist SecuritiesMaintainsBuy—
15 May 2026Leerink PartnersMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IMNM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IMNM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Immunome, Inc. returned +26.7% against +14.8% for the S&P 500, dividends included.

IMNM vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Jan 26Apr 26Jul 26Oct 26IMNMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMNM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
10
Fundamentals

Immunome, Inc. (IMNM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.0×

Cheaper than 93% of US stocks

Price / sales
331.9×

Cheaper than 2% of US stocks

Price / book
4.2×

Cheaper than 22% of US stocks

EV / EBITDA
−6.6×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−3228.8%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−64.0%

Higher than 18% of US stocks

Return on assets
−37.8%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Immunome, Inc. (IMNM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Immunome, Inc. has a market value of $2.3B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$254.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$228.1M.

  • Shares outstanding: 113.4M.

  • Trailing P/E: −8.0×; forward P/E: −7.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Immunome, Inc. employs 247 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Nov 2026

Data provided by Twelve Data

Peers

IMNM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMNMImmunome, Inc.$2.3B33
CLDXCelldex Therapeutics, Inc.$2.3B24
VCELVericel Corp.$2.3B94
RXRXRecursion Pharmaceuticals, Inc.$2.3B61
PVLAPalvella Therapeutics, Inc.$2.3B36
AUPHAurinia Pharmaceuticals, Inc.$2.3B98
ADMAADMA Biologics, Inc.$2.3B60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immunome, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMNM news & analysis

Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know

Zacks Investment Research · 4 Nov 2026positive

Zacks reports that the consensus price target for Immunome (IMNM) suggests about 74% upside potential. It notes that this metric has limited empirical effectiveness, while upward earnings estimate revisions may indicate near-term upside.

Why it matters — IMNM watchers may find the consensus target and recent direction of earnings estimate revisions relevant, alongside Zacks’ caveat about the metric’s effectiveness.

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

Zacks Investment Research · 4 Nov 2026positive

Zacks Investment Research identified Immunome among four biotech stocks with positive Earnings ESPs and favorable Zacks Ranks, suggesting potential to exceed third-quarter earnings estimates.

Why it matters — The item highlights Immunome’s earnings-estimate indicators ahead of its third-quarter results.

Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026

Business Wire · 4 Nov 2026positive

Immunome announced that initial first-in-human clinical data from its ongoing Phase 1 study of investigational ROR1-targeted ADC IM-1021 will be presented at the 68th ASH Annual Meeting. The study is for advanced B-cell lymphomas.

Why it matters — The presentation will provide an update on the early clinical study of an Immunome investigational therapy for advanced B-cell lymphomas.

Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference

Business Wire · 2 Nov 2026neutral

Immunome announced that management will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 9 a.m. EST. A live audio webcast will be available through the Investor Relations section of the company’s website.

Why it matters — The conference presentation provides IMNM watchers an opportunity to hear from company management.

Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

Business Wire · 30 Oct 2026positive

Immunome announced that the European Medicines Agency validated its marketing authorization application for varegacestat, an investigational oral once-daily gamma secretase inhibitor, for adults with desmoid tumors. The EMA validation confirms the application is complete.

Why it matters — The validation marks a regulatory milestone in Immunome’s application for varegacestat in adults with desmoid tumors.

FAQ

Frequently asked questions about IMNM stock

What is the IMNM stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Immunome, Inc. have a median 12-month price target of $36, with estimates ranging from $24 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMNM stock a buy right now?

Of the 17 analysts covering Immunome, Inc., 16 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunome, Inc. 33 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMNM?

As at 4 Nov 2026, Immunome, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (87 of 100).

Will IMNM stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +84.4% from the last close, and Ticker Nerd's factor model ranks Immunome, Inc. 33 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMNM stock forecast for 2030?

No analyst covering Immunome, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $40 over the next 12 months.

How has IMNM stock performed over the past year?

Immunome, Inc. returned +26.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immunome, Inc. do?

Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies.

What is the latest news on IMNM?

The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know". Zacks reports that the consensus price target for Immunome (IMNM) suggests about 74% upside potential. It notes that this metric has limited empirical effectiveness, while upward earnings estimate revisions may indicate near-term upside.

Company

About Immunome, Inc.

Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s work centers on antibody-drug conjugates and other oncology-focused modalities designed to identify and attack specific disease targets while limiting effects on healthy tissue. Its current portfolio includes late-stage and early-stage programs such as varegacestat for desmoid tumors, IM-1021, and additional investigational assets in radiotherapy and solid-tumor antibody-drug conjugates. Immunome also uses proprietary antibody discovery capabilities to support the identification of novel therapeutic candidates and targets. Based in Bothell, Washington, Immunome operates as a research-driven drug development company serving the oncology market through a pipeline of clinical and preclinical assets.

CEO Dr. Clay B. Siegall Ph.D. · 247 employees · United States · https://immunome.com